Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PQR309 |
Synonyms | |
Therapy Description |
PQR309 (Bimiralisib) is a dual pan-PI3K and mTORC1/2 inhibitor, which blocks PI3K/mTOR signaling, potentially resulting in inhibition of tumor growth (PMID: 29066507). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PQR309 | PQR 309|PQR-309|Bimiralisib | mTOR Inhibitor 51 PI3K Inhibitor (Pan) 42 | PQR309 (Bimiralisib) is a dual pan-PI3K and mTORC1/2 inhibitor, which blocks PI3K/mTOR signaling, potentially resulting in inhibition of tumor growth (PMID: 29066507). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02249429 | Phase Ib/II | PQR309 | Open-Label, Non Randomized Phase 2 Study With Safety Run-In | Completed | USA | ISR | GBR | FRA | 2 |
NCT02483858 | Phase I | PQR309 | Study of Oral PQR309 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03740100 | Phase II | PQR309 | Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations (HNSCC) | Terminated | USA | 0 |
NCT02669511 | Phase II | PQR309 | PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma | Completed | 0 |